title: Response-related predictors of survival in CML.
abstract: The assessment of response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) does not only reflect tumor burden at a given time but has been shown to be linked to long-term survival outcomes as well. Therefore, the quantification of molecular or cytogenetic response as early as 3 months on treatment allows a prognostic stratification of a patient's individual risk. With competing TKI regimens available, a timely switch of treatment can be considered if unfavorable outcome has to be expected due to early response failure. Numerous studies have demonstrated the association of long-term outcome with early response for first-line treatment with imatinib, with second-generation TKI and for second-line TKI treatment as well.
authors: III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Pettenkoferstrasse 22, 68169, Mannheim, Germany, benjamin.hanfstein@medma.uni-heidelberg.de.
authors: Benjamin
authors: B
authors: Hanfstein
authors: Martin C
authors: MC
authors: Müller
authors: Andreas
authors: A
authors: Hochhaus
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D016903:Drug Monitoring; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D017410:Practice Guidelines as Topic; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012074:Remission Induction; D018570:Risk Assessment / Q000379:methods
chemical_list: D000970:Antineoplastic Agents; C581634:BCR-ABL1 fusion protein, human; D015415:Biomarkers; D047428:Protein Kinase Inhibitors; D016044:Fusion Proteins, bcr-abl